AU565 [AU-565]細胞

年限： 43 years

運輸方式： 凍存運輸

生長狀態(tài)： 貼壁生長

是否是腫瘤細胞： 0

物種來源： 人

器官來源： **

數量： 大量

ATCC Number： CRL-2351?

相關**： 腺癌

細胞形態(tài)： 上皮樣

Designations: AU565 [AU-565]

Depositors: SS Bacus

AU565 [AU-565]細胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: mammary gland; breast

Disease: adenocarcinoma

Derived from metastatic site: malignant pleural effusion

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Receptors: epidermal growth factor (EGF)

Oncogene: AU565 [AU-565]細胞her2/neu + (overexpressed); her3 +; her4 +; p53 +

DNA Profile (STR): Amelogenin: X

CSF1PO: 12

D13S317: 11,12

D16S539: 9

D5S818: 9,12

D7S820: 9,12

THO1: 8,9

TPOX: 8,11

vWA: 17

Age: 43 years

Gender: female

Ethnicity: Caucasian, White

Comments: The AU565 cell line was derived at the Naval Biosciences Laboratory, Oakland, CA from a pleural effusion of a patient with breast carcinoma. AU565 [AU-565]細胞This cell line was established from the same patient as SK-BR-3 (ATCC HTB-30).

The patient, a White, Caucasian female, age 43, blood type A+, had been treated with radiation, steroids, cytoxan and 5-fluorouracil.

The AU565 cell line amplifies and overexpresses the HER-2/neu oncogene; it expresses the HER-3, HER-4 and p53 oncogenes.

The cells are useful as models of cellular growth to study the differentiation of breast cancer cells.

Treating the cells with mycophenolic acid (MPA), phorbol 12-myristate 13-acetate (PMA), retinoic acid (RA) or the TA-1 monoclonal antibody to the extracellular domain of the HER-2/neu protein can induce cell differentiation. [38764]

Treatment of AU565 cells with Neu differentiation factor (NDF) also induces mature phenotype, which is characterized by the morphological appearance of the cells. [38770]

Untreated AU565 cells have compact nuclei with thin cytoplasm while treated cells display a morphology associated with a differentiated phenotype such as flat large nuclei surrounded by a sizable cytoplasm.

A culture submitted to the ATCC in April of 1995 was found to be contaminated with mycoplasma and progeny were cured by a 21-day treatment with BM Cycline.

The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended

Medium Renewal: Every 3 to 5 days

Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. AU565 [AU-565]細胞Allow the flask to sit at room temperature (or at 37C) until the cells detach.

Add fresh culture medium, aspirate and dispense into new culture flasks.

Preservation: culture medium 95%; DMSO, 5%

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

derived from same individual:ATCC HTB-30

References: 38764: Bacus SS, et al. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol. Carcinog. 3: 350-362, 1990. PubMed: 1980588

38765: Bacus SS, et al. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res. 52: 2580-2589, 1992. PubMed: 1373672

38766: Bacus SS, et al. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res. 53: 5251-5261, 1993. PubMed: 8106145

38768: Wen D, et al. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69: 559-572, 1992. PubMed: 1349853

38769: Bacus SS, et al. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ. 3: 401-411, 1992. PubMed: 1358180

38770: Peles E, et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69: 205-216, 1992. PubMed: 1348215

38774: Lessor T, et al. Regulation of heregulin beta1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway. J. Cell. Biochem. 70: 587-595, 1998. PubMed: 9712155

38775: Yoo JY, et al. Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines. Breast Cancer Res. Treat. 51: 71-81, 1998. PubMed: 9877030

38776: Yoo JY, Hamburger AW. Changes in heregulin beta1 (HRGbeta1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line. Mol. Cell. Endocrinol. 138: 163-171, 1998. PubMed: 9685225